Sarepta Therapeutics Inc. (NASDAQ:SRPT) was upgraded by investment analysts at Jefferies Group from an “underperform” rating to a “hold” rating in a research note issued to investors on Monday. The firm presently has a $50.00 target price on the stock. Jefferies Group’s price objective points to a potential downside of 10.28% from the stock’s current price.
Several other research firms have also weighed in on SRPT. SunTrust Banks Inc. upgraded shares of Sarepta Therapeutics from a “reduce” rating to a “neutral” rating in a research note on Wednesday, September 14th. JMP Securities reiterated an “underperform” rating and issued a $10.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, September 15th. Piper Jaffray Cos. upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Monday. Royal Bank Of Canada upgraded shares of Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating and set a $83.00 price target on the stock in a research note on Monday. Finally, William Blair upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $88.00 price target on the stock in a research note on Monday. Two analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Sarepta Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $51.01.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 55.73 on Monday. The company’s market cap is $2.67 billion. The stock has a 50 day moving average of $28.17 and a 200 day moving average of $21.37. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $56.80.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the business posted ($0.87) EPS. On average, equities analysts anticipate that Sarepta Therapeutics will post ($4.98) earnings per share for the current fiscal year.
In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 24,557 shares of the stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the completion of the sale, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.90% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the stock. State Street Corp increased its stake in shares of Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock worth $48,168,000 after buying an additional 865,658 shares during the period. Franklin Resources Inc. bought a new stake in shares of Sarepta Therapeutics during the first quarter worth $13,506,000. A.R.T. Advisors LLC bought a new stake in shares of Sarepta Therapeutics during the first quarter worth $7,461,000. Eagle Asset Management Inc. bought a new stake in shares of Sarepta Therapeutics during the second quarter worth $6,756,000. Finally, Emerald Mutual Fund Advisers Trust bought a new stake in shares of Sarepta Therapeutics during the second quarter worth $4,712,000. 72.09% of the stock is owned by hedge funds and other institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.